Navigation Links
DelMar Pharmaceuticals Announces Acquisition and $5.4 Million Private Placement to Advance Novel Cancer Therapies
Date:1/25/2013

VANCOUVER, British Columbia and MENLO PARK, Calif., Jan. 25, 2013 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (OTCQB: BRRY) ("DelMar") today announced the successful acquisition (the "Acquisition"), through a share exchange agreement, of all of the outstanding shares of Del Mar Pharmaceuticals (BC) Ltd., a clinical and commercial stage drug development company with a focus on the treatment of cancer.  Concurrent with the Acquisition, DelMar completed the first closing in a private placement consisting of approximately 6.7 million units of its securities to qualified accredited investors, for total gross proceeds of approximately $5.4 million.

DelMar will be quoted on the OTC QB under the symbol "BRRY" beginning January 25th, 2013; the symbol will be changed to "DMPI" on or about January 31, 2013.

Charles Vista LLC acted as the company's placement agent in the unit offering. Each unit consists of one share of common stock and one common stock purchase warrant.

"DelMar is pleased to achieve this important milestone," stated Jeffrey Bacha , Chief Executive Officer of DelMar. "Becoming a publicly traded company will allow for broad and diversified investor exposure and access to the capital markets.  These funds will position us to expand and accelerate our drug development activities with our lead drug candidate, VAL-083.  Our company and our management are committed to creating shareholder value by executing on our mission to rapidly develop and commercialize proven cancer therapies in new orphan drug indications in areas of significant unmet medical need, particularly where patients have failed modern targeted medicines."

VAL-083, represents a "first in class" small-molecule chemotherapeutic, which means that the molecular structure of VAL-083 is not an analogue or derivative of other small molecule chemotherapeutics approved for
'/>"/>

SOURCE DelMar Pharmaceuticals
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
2. Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944
3. TetraLogic Pharmaceuticals Announces Initiation of a Phase 1/2 Clinical Trial of TL32711 in Patients with Acute Myelogenous Leukemia (AML)
4. Questcor Pharmaceuticals to Present at the Oppenheimer Healthcare Conference on December 13, 2011
5. Synergy Pharmaceuticals, Inc. Files Suit Against Ironwood Pharmaceuticals, Inc. and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie
6. Acumen Pharmaceuticals Regains Worldwide Rights to Anti-ADDL Antibody Therapeutics and Diagnostics for Alzheimers Disease From Merck
7. Inspiration Biopharmaceuticals Moves Corporate Headquarters to Cambridge, Massachusetts
8. Ampio Pharmaceuticals Awarded Canadian Composition of Matter Patent That Strengthens IP Protection for Its Key Drug Ampion™
9. Amylin Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference
10. Inovio Pharmaceuticals Promotes Niranjan Sardesai to Chief Operating Officer
11. Keryx Biopharmaceuticals to Present at JP Morgans 30th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/6/2015)... Strategic marketing and branding agency, Red ... Able&Co. , The agency was founded in 2008 by ... inception, continuing to expand its business each year. “We ... a core focus on branding and marketing strategy. As ... and visual identity to reflect who we have become ...
(Date:3/6/2015)... March 6, 2015   InspireMD, Inc. (NYSE MKT: ... systems, announced today that it will release its full financial ... 2014 on Thursday, March 12 th after market close, ... review its financial results and business outlook. Participants ... or (412) 542-4135 (International) and request the InspireMD call. A ...
(Date:3/6/2015)... According to a new market research report ... Xenograft, Suture Anchor, Interference Screws, Laparoscopic Instruments) by Application ... Global Forecast to 2019", published by MarketsandMarkets, the Soft ... in 2019 from $10.3 Billion in 2014, at a ... Browse 70 market data tables and 32 ...
(Date:3/6/2015)... St. Paul, Minn. (PRWEB) March 06, 2015 ... cutting edge Scientific Symposia sessions for the grain ... call for abstracts. , 2015 marks the ... holding its Centennial Meeting in Minneapolis, Minnesota, U.S.A. ... forward-thinking presentations from international researchers who are looking ...
Breaking Biology Technology:Red House Group Reveals New Identity as Able&Co. 2InspireMD to Report Financial Results for the Fourth Quarter and Year Ended December 31, 2014 on Thursday, March 12th 2Soft Tissue Repair Market worth $14.7 Billion in 2019 2Soft Tissue Repair Market worth $14.7 Billion in 2019 3Soft Tissue Repair Market worth $14.7 Billion in 2019 4AACCI Unveils Scientific Symposia Sessions for Centennial Meeting 2
... first to provide high coverage and megabase capacity ... HEIDELBERG, Germany, March 16 febit ... sequence capture technology HybSelect. In several biomedical studies ... HybSelect demonstrated superb enrichment factors and deep sequencing ...
... Helix BioPharma Corp. (TSX, FSE: "HBP") announced ... in Germany to initiate its planned Phase II ... with low-grade cervical lesions.The clinical study was designed, ... on the absorption and elimination profile of Topical ...
... Announces that Approximately 89.3 Percent of Outstanding Indevus ... March 16 Endo Pharmaceuticals (Nasdaq: ... p.m., New York City time, on March 13, ... notices of guaranteed delivery) were validly tendered and ...
Cached Biology Technology:Automated Sequence Capture for Next-Generation Sequencing Paves the Way for Personalized Medicine 2Automated Sequence Capture for Next-Generation Sequencing Paves the Way for Personalized Medicine 3Helix BioPharma Receives Approval to Initiate Phase II Pharmacokinetic Clinical Study of Topical Interferon Alpha-2b in Patients with Low-Grade Cervical Lesions 2Helix BioPharma Receives Approval to Initiate Phase II Pharmacokinetic Clinical Study of Topical Interferon Alpha-2b in Patients with Low-Grade Cervical Lesions 3Helix BioPharma Receives Approval to Initiate Phase II Pharmacokinetic Clinical Study of Topical Interferon Alpha-2b in Patients with Low-Grade Cervical Lesions 4Helix BioPharma Receives Approval to Initiate Phase II Pharmacokinetic Clinical Study of Topical Interferon Alpha-2b in Patients with Low-Grade Cervical Lesions 5Endo Pharmaceuticals Extends Subsequent Offering Period for Indevus Shares Until 5:00 pm EDT on Wednesday, March 18, 2009 2Endo Pharmaceuticals Extends Subsequent Offering Period for Indevus Shares Until 5:00 pm EDT on Wednesday, March 18, 2009 3
(Date:3/5/2015)... 2015 In Brazil , cloud ... using these solutions and 42 percent planning to invest in ... 25 percent of the companies will be investing in these ... of companies in the region are currently opting for the ... will command significant attention in the coming years. This trend ...
(Date:3/4/2015)... Research and Markets ( http://www.researchandmarkets.com/research/48tj8z/global_biometrics ... "Global Biometrics Market Forecast and Opportunities, 2020" ... for biometric authentication systems is projected to grow ... The driving forces for this highly ... projects and constant development in technology. In 2014, ...
(Date:3/3/2015)... Calif. , March 3, 2015 /PRNewswire/ ... leading provider of advanced cryogenic logistics solutions ... including immunotherapies, stem cells, cell lines, clinical ... reproductive medicine, today announced the expansion of ... Research Centers, ("Fred Hutch") Clinical Research ...
Breaking Biology News(10 mins):Two of Every Three Brazilian Companies will have Invested in Cloud by 2015, Finds Frost & Sullivan 2Two of Every Three Brazilian Companies will have Invested in Cloud by 2015, Finds Frost & Sullivan 3Two of Every Three Brazilian Companies will have Invested in Cloud by 2015, Finds Frost & Sullivan 4Global Biometrics Market Forecast and Opportunities, 2020 2Global Biometrics Market Forecast and Opportunities, 2020 3Cryoport, Inc. Expands Support of Fred Hutchinson Cancer Research Center's Clinical Research Division 2Cryoport, Inc. Expands Support of Fred Hutchinson Cancer Research Center's Clinical Research Division 3
... , ITHACA, N.Y. Cornell University researchers may have solved ... blood-brain barrier so that therapies to treat Alzheimer,s disease, multiple ... be delivered. ( Journal of Neuroscience , Sept. 14, 2011.) ... by the body, can modulate the entry of large molecules ...
... The onset of inflammation and infection in a person ... severe burns can be as deadly as the incident itself. ... in trauma victims may help to predict and better treat ... 13 issue of the journal PLoS Medicine shows ...
... Yukon River Basin provide unique insights on climate change ... local communities. The USGS coordinated interviews with ... Mary,s and Pitka,s Point, Alaska, to document their observations ... such as unpredictable weather patterns and dangerous ice conditions, ...
Cached Biology News:Breaching the blood-brain barrier 2Gene flux can foretell survival for trauma patients, Princeton study finds 2Gene flux can foretell survival for trauma patients, Princeton study finds 3Gene flux can foretell survival for trauma patients, Princeton study finds 4Gene flux can foretell survival for trauma patients, Princeton study finds 5Gene flux can foretell survival for trauma patients, Princeton study finds 6Gene flux can foretell survival for trauma patients, Princeton study finds 7Observations of climate change from indigenous Alaskans 2Observations of climate change from indigenous Alaskans 3
... versatile enclosures are designed ... or other process gas ... environment. HEPA filtration, heating/cooling, ... modules also available, along ...
... ideal modular cleanroom for biological safety ... require cleanliness (to Class 10/ISO 3) ... to create ultra-smooth surfaces that are ... One-inch radius corners simplify cleaning. Unique ...
... unit provides continuous vertical flow of 99.99% ... 5) cleanliness standards , Stainless ... disinfect , Large, ergonomically sloped ... insertion of filling machines or other large ...
This modular benchtop fume hood ventilates and purifies chemical fumes, allowing safe indoor release of exhaust. Bonded charcoal filters remove most organic contaminants. Options include final HEPA f...
Biology Products: